Health Care [ 4/12 ] | Biotechnology [ 15/74 ]
NASDAQ | Common Stock
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
The company has collaborations and licensing agreements with F.
Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 18, 25 | 1.26 Increased by +53.66% | 1.16 Increased by +8.73% |
| Oct 31, 24 | 1.27 Increased by +69.33% | 0.98 Increased by +29.59% |
| Aug 6, 24 | 0.91 Increased by +22.97% | 0.76 Increased by +19.74% |
| May 7, 24 | 0.79 Increased by +68.09% | 0.70 Increased by +12.86% |
| Feb 20, 24 | 0.82 Increased by +70.83% | 0.83 Decreased by -1.20% |
| Nov 6, 23 | 0.75 Increased by +1.35% | 0.71 Increased by +5.63% |
| Aug 8, 23 | 0.74 Increased by +39.62% | 0.63 Increased by +17.46% |
| May 9, 23 | 0.47 Increased by 0.00% | 0.48 Decreased by -2.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 298.01 M Increased by +29.55% | 137.01 M Increased by +60.46% | Increased by +45.98% Increased by +23.86% |
| Sep 30, 24 | 290.08 M Increased by +34.28% | 137.01 M Increased by +67.42% | Increased by +47.23% Increased by +24.68% |
| Jun 30, 24 | 231.35 M Increased by +4.67% | 93.25 M Increased by +24.74% | Increased by +40.30% Increased by +19.17% |
| Mar 31, 24 | 195.88 M Increased by +20.81% | 76.82 M Increased by +93.92% | Increased by +39.22% Increased by +60.52% |
| Dec 31, 23 | 230.04 M Increased by +26.75% | 85.39 M Increased by +47.98% | Increased by +37.12% Increased by +16.75% |
| Sep 30, 23 | 216.03 M Increased by +3.38% | 81.84 M Increased by +32.78% | Increased by +37.88% Increased by +28.44% |
| Jun 30, 23 | 221.04 M Increased by +45.07% | 74.75 M Increased by +229.53% | Increased by +33.82% Increased by +127.15% |
| Mar 31, 23 | 162.14 M Increased by +38.25% | 39.62 M Decreased by -34.09% | Increased by +24.43% Decreased by -52.33% |